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1.0 INTRODUCTION
There has been increasing recognition of the
potential benefits of liver resection for colorectal
metastases in the UK although this treatment
has been established more widely in other
Western countries. There are no randomised
studies assessing outcome following resection
compared with no treatment or other therapeutic
modalities in patients with known resectable
liver metastases as it is generally considered
unethical not to offer surgery for resectable
disease. There has been increased interest in
more aggressive chemotherapy regimens that
have been reported to not only control metastatic
disease but also to render some advanced liver
metastases resectable.1–4 Furthermore, other new
modalities have become available that allow safe
ablation of liver metastases without the need for
surgical intervention. There is therefore a need to
produce clear guidelines on the appropriate
management of patients with colorectal cancer
who have been shown to have hepatic metastases.
These guidelines are intended to address a
number of issues:
(a) the principles under which patients with
hepatic metastases should be managed;
(b) which patients who have undergone
attempted curative resection of the primary
colorectal tumour should be offered sur-
veillance;
(c) what investigations are required to deter-
mine appropriate management; and
(d) which treatment modality is most appro-
priate in a given clinical context.
2.0 FORMULATION OF GUIDELINES
The process of formulating any clinical guide-
lines requires a guideline development group, a
search strategy with review of the relevant
literature, synthesis of evidence (and consensus
methods for topics when evidence is lacking),
followed by external review. A multidisciplinary
meeting with representation from a number of
interested bodies involving surgeons, gastroen-
terologists, oncologists, diagnostic and interven-
tional radiologists, pathologists, general
practitioners, clinical nurse specialists, nurse
practitioners, and patients was held in the
Pelican Centre in Basingstoke on 2–4 October
2003 (see appendix 1). The Appraisal of
Guidelines Research and Evaluation (AGREE)
instrument was used to provide a framework for
assessing the quality of the clinical practice
guidelines. At this initial meeting, discussion
resulted from individual presentations on aspects
of hepatic metastases, a literature review, and
expert re-evaluation. The literature review has
been published in the British Journal of Cancer.5 An
initial group consensus was reached and a
preliminary document produced before this was
further refined by the group on 12 March 2004.
This document has undergone subsequent expert
external review and been amended accordingly.
This guideline is not intended to serve as a
standard of care as such standards are deter-
mined on the basis of all clinical data available
for the individual case. It is recognised that they
are subject to change with advances in scientific
knowledge and technology and as patterns of
care evolve. These parameters of clinical practice
should be considered as guidelines only. The
critical judgement regarding a particular clinical
procedure or treatment plan has to be made by
the doctor and the multidisciplinary team,
following discussion of the options with the
patient, and in the light of the diagnostic and
therapeutic choices available. However, it is
advised that significant departures from these
guidelines be documented in the patient’s case
records at the time the relevant decision is taken.
This guideline was issued in 2005 and will be
reviewed periodically and no later than 2008 to
reflect any new evidence. The strength and
evidence used in these guidelines was that used
by the Agency for Health Policy Research (1992).
3.0 CATEGORIES OF EVIDENCE
N Ia: evidence from meta-analysis of ran-
domised controlled trials.
N Ib: evidence from at least one randomised
controlled trial.
N IIa: evidence from at least one controlled
study without randomisation.
N IIb: evidence from at least one other type of
quasi-experimental study.
N III: evidence from non-experimental descrip-
tive studies, such as comparative studies,
correlation studies, and case control studies.
N IV: evidence from expert committee reports or
opinions and/or clinical experience of
respected authorities.
4.0 DERIVED STRENGTHS OF
RECOMMENDATION
N A: directly based on category I evidence.
N B: directly based on category II evidence or
extrapolated recommendation from category I
evidence.
Abbreviations: MDT, multidisciplinary meeting; CT,
computed tomography; CEA, carcinoembryonic antigen;
MRI, magnetic resonance imaging; FDG, F-18
fluorodeoxyglucose; PET, positron emission tomography;




N C: directly based on category III evidence or extrapolated
recommendation from category I or II evidence.
N D: directly based on category IV evidence or extrapolated
recommendation from category I, II, or III evidence.
5.0 SUMMARY OF RECOMMENDATIONS
5.1. General
N Patients under consideration of treatment of hepatic
metastases should be discussed at a multidisciplinary
meeting which has experience in the management of liver
metastases.
N A hepatobiliary multidisciplinary team (MDT) which
carries out liver resection should be based in a cancer
centre serving a population of at least two million. When
two or three networks cooperate to create a single joint
team, there should be explicit arrangements for referral
between networks. (Category of evidence II ; strength of
recommendation B)
N Consideration of patients for resection of liver metastases
should be carried out at a single high volume centre.
(Category of evidence II; strength of recommendation B)
5.2 At time of presentation of primary colorectal
cancer
N Patients with primary colorectal cancer should have a
computed tomography (CT) scan of the abdomen and
pelvis performed with intravenous contrast and ideally a
maximum collimation of 5 mm. This should be performed
preoperatively or, in the case of an emergency, as soon as
practical thereafter. (Category of evidence II; strength of
recommendation B)
N A chest CT is ideal to assess the presence of pulmonary
metastases but a chest x ray is considered satisfactory.
(Category of evidence III; strength of recommendation C)
N The whole of the colon should be visualised to ensure a
‘‘clean colon’’. (Category of evidence II; strength of
recommendation B)
N A baseline measurement of carcinoembryonic antigen
(CEA) should be performed. (Category of evidence III;
strength of recommendation C)
5.3 Following curative resection of primary colorectal
cancer
N Following treatment of the primary disease, some patients
will prove to be unfit or unwilling to have further
treatment and in such cases follow up is inappropriate.
N Other patients will prove to have metastatic disease at
presentation. Some of these will have isolated liver
metastases and should be managed as described in these
guidelines.
N Patients undergoing R0 colorectal resection may be
candidates for adjuvant chemotherapy and a further
abdominal contrast enhanced CT (or magnetic resonance
imaging (MRI)) should be performed following comple-
tion of chemotherapy. (Category of evidence III; Strength
of recommendation C)
N Where possible patients over the age of 50 years should be
considered for randomisation to the FACS trial, the UK
NCRN trial of follow up strategies (synopsis in appendix
2).
N If the patient is ineligible for trial inclusion, does not wish
to participate in the randomised trial, or if the unit is not
recruiting to the trial, the following follow up schedule is
appropriate6:
(a) CT scan of the abdomen and pelvis should be under-
taken as a minimum in the two years following
completion of treatment of the primary disease.
(Category of evidence III; strength of recommendation
C)
(b) Colonoscopy repeated after five years.
(c) The case for routine serial CEA measurements is
unproven. (Category of evidence III; strength of
recommendation C)
5.4 Further staging investigation to detect
extrahepatic involvement in patients with colorectal
l iver metastases
N For a patient discovered to have isolated liver metastases,
CT of the chest, abdomen, and pelvis should be performed
by the liver surgery unit or using protocols agreed with
that unit. The liver surgery centre will also often perform
liver specific imaging by local protocol.
N Biopsy of hepatic lesions should not be performed without
discussion with the regional hepatobiliary unit. (Category
of evidence III; strength of recommendation C)
N Patients with ‘‘high risk’’ primary disease (T4 (perfor-
ated); C2 (apical node)) should have careful preoperative
investigations that might include positron emission
tomography (PET) and laparoscopy. (Category of evidence
III; strength of recommendation C)
5.5 Liver resection for colorectal metastases
N The aim of liver resection (resectability) is to remove all
macroscopic disease with clear (negative) margins and
leave sufficient functioning liver. (Category of evidence II;
strength of recommendation B)
N Patients with solitary, multiple, and bilobar disease who
have had radical treatment of the primary colorectal
cancer are candidates for liver resection. (Category of
evidence III; strength of recommendation C)
N The ability to achieve clear margins (R0 resection) should
be determined by the radiologist and surgeon in the
regional hepatobiliary unit. (Category of evidence III;
strength of recommendation C)
N The surgeon should define the acceptable residual
functioning volume, approximately one third of the
standard liver volume, or the equivalent of a minimum
of two segments. (Category of evidence III; strength of
recommendation C)
N The liver surgeon and anaesthetist should take the clinical
decision regarding fitness for surgery. (Category of
evidence III; strength of recommendation C)
N If deemed medically unfit for surgery, patients should be
considered for ablative therapy. (Category of evidence IV;
strength of recommendation D)
N Patients with extrahepatic disease that should be con-
sidered for liver resection include:
(1) resectable/ablatable pulmonary metastases;
(2) resectable/ablatable isolated extrahepatic sites—for
example, spleen, adrenal, or respectable local recurrence;
and
(3) local direct extension of liver metastases to, for example,
diaphragm/adrenal that can be resected. (Category of
evidence IV; strength of recommendation D)
N Normal contraindications to liver resection would include
uncontrollable extrahepatic disease such as:
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– non-treatable primary tumour;
– widespread pulmonary disease;
– locoregional recurrence;
– peritoneal disease;
– extensive nodal disease, such as retroperitoneal, med-
iastinal or portal nodes; and
– bone or CNS metastases. (Category of evidence II;
strength of recommendation B)
5.6 Tumours borderline for resection
N Those patients with tumours thought to be borderline for
resection may have resectable or ablatable disease and
should be referred for discussion with the regional
hepatobiliary unit before chemotherapy. (Category of
evidence III; strength of recommendation C)
N Resectability may be achieved by portal vein embolisation
or two stage hepatectomy to increase hepatic functional
reserve and also by combinations of surgery and ablation.
(Category of evidence IV; strength of recommendation D)
5.7 Ablative therapy
N The decision to offer ablative therapy to patients with
hepatic metastases should be made by the regional
hepatobiliary unit.
N Patients who are not candidates for resection should be
considered for the CLOCC (chemotherapy + local ablation
versus chemotherapy) trial.
N Entry into the CLOCC trial should be considered for
patients with nine or less metastases (up to 4 cm) without
extrahepatic disease (EORTC 40004).
N Patients who are not suitable for entry to the CLOCC trial
may be considered for ablative therapy. (Category of
evidence IV; strength of recommendation D)
5.8 Patients not suitable for resection or ablative
therapy
N Patients with advanced disease unsuitable for liver
resection or ablative therapy should be referred to the
clinical or medical oncologist with a special interest in
colorectal cancer for further management and supportive
care.(Category of evidence II; strength of recommendation
B)
5.9 Synchronous metastases
N Normally, colorectal cancer resection and liver resection
would not be performed synchronously. However, man-
agement of accessible small metastases detected preopera-
tively should be discussed with the local liver centre for
consideration of combined resection.
N Lesions discovered at operation should not be biopsied.
(Category of evidence III; strength of recommendation C)
N Excision of small atypical lesions should not be considered
without discussion with the regional hepatobiliary unit.
N Patients should be referred for consideration of liver
resection after recovery from primary surgery.
N Patients with potentially resectable liver disease and who
have undergone radical resection of the primary tumour
should be considered for liver resection before considera-
tion of chemotherapy.
N Patients with unfavourable primary pathology such as
perforated primary tumour or extensive nodal involvement
should be considered for adjuvant chemotherapy prior to
liver resection and be restaged at three months.
5.10 Histopathology
N The histopathology report of the resected liver specimen
must include specific details which can be used to
determine prognosis.
N These should include number, size, and location of
metastases, resection margin clearance from tumour,
capsular invasion, degree of differentiation, presence of
necrosis, vascular and lymphatic invasion, and lymph
node status if sampled. (Category of evidence II; strength
of recommendation B)
5.11 Follow up after liver resection
N Follow up would normally continue for five years
according to local protocol using CT chest and liver and
CEA. Follow up should be performed by the liver centre or
the referring unit following an agreed protocol. Any
abnormality should be referred back to the liver centre
for consideration of re-resection or ablation. (Category of
evidence III; strength of recommendation C)
N In patients who develop recurrence, it seems appropriate
to consider such lesions in the same way as the initial
hepatic metastases and offer re-resection or ablation to
patients based on operative risk and likely survival.
(Category of evidence III; strength of recommendation C)
6.0 BACKGROUND
Colorectal cancer is the commonest gastrointestinal malig-
nancy and the second commonest cause of cancer death,
comprising 11% of new cancer diagnoses and 10% of all
cancer deaths in the UK. Approximately 32 000 cases are
diagnosed each year and 17 000 deaths are attributed to the
disease. The liver is often the first site of metastatic disease
and may be the only site of spread in as many as 30–40% of
patients with advanced disease.7 Of new cases, 20–25% of
patients will have clinically detectable liver metastases at the
time of the initial diagnosis and a further 40–50% of patients
will eventually develop liver metastases after resection of the
primary, most commonly within the first three years of
follow up.8–11 It has been postulated that the principal mode
of tumour dissemination is via the portal system and
therefore that surgical resection of isolated hepatic metas-
tases from colorectal cancer may be curative in a number of
cases.7
The natural history of metastatic colorectal cancer is
variable. Median survival without treatment is less than
eight months from presentation but the prognosis is better
for those patients with isolated hepatic metastases.12 Patients
with a limited number of metastases or those with disease
confined to one lobe of the liver have a longer duration of
survival than those with more advanced disease.8 10 13
However, even in the group of patients with limited
metastatic liver disease, survival at five years is exceptional.14
Approximately 20–30% of patients with metastatic colo-
rectal cancer have disease that is confined to the liver and is
potentially resectable.10 Several recent large series on resec-
tion for colorectal liver metastases (CRLM) have reported five
year survival ranging from 25% to 44%, with operative
mortality of 0–6.6%.8 15–17 Given that approximately 18 000
patients will develop hepatic metastases annually in the UK,
approximately 3600 patients may be suitable for hepatic
resection although many more patients may benefit from
hepatic resection with less restrictive criteria of resectability
being employed in many centres.16 It seems unlikely that a
randomised study assessing outcome following resection
compared with other treatments modalities will be under-
taken in patients with known resectable liver metastases but
there has been increased interest in new chemotherapy
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regimens1–4 and other new modalities that allow safe ablation
of liver metastases.
7.0 MULTIDISCIPLINARY TEAMS
It is accepted that the management of all patients with
colorectal cancer should be the responsibility of colorectal
cancer MDTs and that any patient under the care of a
clinician who is not a member of such an MDT should be
referred immediately to an appropriate team when colorectal
cancer is suspected.18 19 It has been advocated that such
colorectal MDTs should identify or establish a specialised
hepatobiliary MDT which has the expertise and facilities to
provide surgery for patients with liver metastases. Several
large studies on resection for colorectal liver metastases
(CRLM) have reported lower operative mortality than that
reported in previous decades.8 10 15 17 20 While this is likely to
be due to a number of factors, there have been a several
recent studies which have demonstrated a volume effect on
outcome, particularly for major upper gastrointestinal resec-
tions. A recent study has shown a similar effect for both short
and long term outcome for patients subjected to major
hepatic resection.21
Membership of the liver resection or hepatobiliary MDT
has been defined in Improving Outcomes in Upper
Gastrointestinal Cancers but would normally consist of at least
two specialist surgeons trained in and maintaining a special
interest in liver resection surgery and who can demonstrate a
high level of skill and training in this area. The team should
also include an oncologist, diagnostic and interventional
radiologist with an expertise in hepatobiliary disease,
histopathologist, and clinical nurse specialist.
8.0 DETECTION OF HEPATIC AND OTHER
METASTASES
Hepatic metastases may be evident at the time of initial
presentation or declared at subsequent follow up. It is
established that a contrast CT scan of the abdomen has
detection rates for hepatic metastases of 68–91% (70%
detection for lesions . 1 cm), and has replaced ultrasono-
graphy as the preferred imaging modality.22 However, the
sensitivity and specificity of CT liver will vary, depending on
the equipment and contrast enhancement methods. MRI can
be used as an alternative for assessing the liver. A recent
meta-analysis to obtain sensitivity estimates of various
imaging modalities for detection of colorectal metastases
showed that F-18 fluorodeoxyglucose (FDG) PET had
significantly higher sensitivity on a per patient basis but
not on a per lesion basis compared with other modalities.23
Sensitivity estimates for MRI imaging with contrast agent
were significantly superior to those for helical CT with 45 g of
iodine or less.23
A chest CT is ideal to assess the presence of pulmonary
metastases but the positive yield of CT scan in patients with a
normal chest x ray at the time of presentation with
potentially resectable liver metastases from colorectal cancer
is only 5%.24 Complete colonic examination by colonoscopy,
CT pneumocolon, or barium enema should be carried out,
ideally in the preoperative period in patients with colorectal
cancer as there is a significant risk of recurrent tumour or of a
metachronous lesion.19 Given that measurement of CEA
levels may be useful in the follow up of colorectal cancer
patients, it is desirable to establish whether levels are
elevated at the time of initial presentation.25
Patients who have undergone apparently curative resection
of colorectal cancer may be followed up to detect metastatic
disease in the expectation that early detection and treatment
will result in improved survival. However, uncertainty
remains as all the randomised trials are considered to have
inadequate numbers.25 Meta-analysis performed as a
Cochrane Review25 and by others26 suggests that there may
be a survival benefit of follow up for metastatic disease but
the heterogeneity of the trials make firm conclusions
impossible. Further studies are required. Although the use
of ultrasonography, CT, or even MRI to detect recurrence or
metastatic disease is very variable,27–29 interval CT scanning
and serial CEA levels appear to be the most promising in this
respect.25 26 Current evidence suggests that an ultrasound
examination of the liver is not sufficiently sensitive to
exclude the presence of metastases.11 CEA may be elevated
in up to 90% of patients with liver metastases11 30 and a rise in
CEA after an initial fall following surgery may be the first
indication of local or distant recurrence in an otherwise
asymptomatic patient. However, a rising CEA concentration
may be a relatively late phenomenon in patients with liver
metastases.
For a patient discovered to have isolated liver metastases, a
CT of the chest, abdomen, and pelvis should be performed by
the liver surgery unit or using protocols agreed with that unit.
The liver surgery centre will also often perform liver specific
imaging by local protocol but biopsy of hepatic lesions should
not be performed without discussion with the regional
hepatobiliary unit. There is evidence that percutaneous
biopsy of liver tumours may be associated with extrahepatic
dissemination of tumour and result in a reduced prospect of
long term survival even when resection of hepatic metastases
is undertaken.31–34 Patients with aggressive primary disease
should have careful preoperative investigations. Laparoscopy
may identify occult metastatic disease and prevent unneces-
sary laparotomy in some patients with potentially resectable
colorectal liver metastases31 35–37 although it may be used
more selectively in patients with a low risk of tumour.35
Laparoscopic ultrasound may provide additional information
in selected patients.31 35 FDG-PET has been used both to
identify the presence of hepatic colorectal metastases38 and to
improve the staging of patients under consideration of
resection of colorectal metastases.39 It is evident that PET
may miss small hepatic lesions and its performance is
affected by recent or current administration of chemother-
apy. Although the evidence for patient benefit is lacking, it is
apparent that it may have a role in the patient at high risk of
extrahepatic dissemination of tumour.40–42
9.0 LIVER RESECTION FOR COLORECTAL
METASTASES
Operative morbidity and mortality following liver resection
are related to the development of hepatic failure that is a
function of the extent of resection43–46 and the presence of
coexisting liver disease.47 Other complications that may
contribute to or be related to postoperative liver failure
include haemorrhage, bile leak, intra-abdominal sepsis, and
cardiopulmonary dysfunction.9 20 47 48 Laparoscopic liver
resection may have some advantage in the short term over
open surgery but there are no data to indicate the impact of
this procedure on long term outcome.49 Duration of survival is
shortened by the presence of inadequate or involved resection
margins.50 Previous data from the Registry of Hepatic
Metastases, a multi-institutional database of liver resections,
suggested that a margin .1 cm was associated with 45% five
year survival, but only 23% survived five years if the margin
was less.51 A number of other studies have supported the view
that poorer overall survival and disease free five year survival
is associated with resection margins less than 1 cm although
others have produced evidence to suggest that a lesser margin
may be acceptable as long as the tumour pseudocapsule is
resected during dissection.48 52 53
Studies have shown that long term survival is achieved in
patients whose primary colorectal cancer has been managed
by radical resection and appropriate local adjuvant treatment.
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There is no evidence that the number or location of the liver
deposits compromises survival in such patients as long as all
macroscopic disease is resected. It has been argued that the
limiting factor to the number of lesions that can be resected is
whether it is technically possible to remove all tumours.8
Long term survival may be affected adversely by the presence
of more than three metastases but multivariate analysis has
provided inconsistent results as to whether the number of
resected metastases has a significant effect on long term
survival.8 16 20 51 54
Resectability of liver tumours requires assessment by a
radiologist in conjunction with a liver surgeon experienced in
the management of colorectal metastases as there is a need to
define the acceptable residual functioning volume. It is
accepted that prediction of liver dysfunction following liver
resection is difficult to quantify for the individual patient.
Previous studies have suggested that that liver volume can be
readily calculated by CT volumetry.43 44 Based on liver
transplant and liver resectional experience, acceptable resi-
dual functioning volume is thought to consist of approxi-
mately one third of the standard liver volume or the
equivalent of two liver segments. Such decisions are again
best made by the hepatobiliary team.
As for most surgical procedures, the operating surgeon and
the anaesthetist are best able to assess the patient’s fitness
for intervention. Increasing ASA and POSSUM grade have
been shown to be of value for several operative procedures.55
Experience of the managing team is likely to have an effect
on outcome and it has been demonstrated that patients who
undergo liver resection at low volume hospitals are at a
higher risk of postoperative complications and death than
those who have the same operation at high volume
hospitals.21
For those patients not considered fit for operative inter-
vention, radiofrequency ablation has been shown to be a safe
and effective treatment for patients unsuitable for liver
resection.56 57 However, its precise role in the management of
hepatic colorectal metastases as yet to be defined and no
study has addressed its potential superiority over other
treatment modalities in the setting of a randomised
controlled trial. Therefore, patients should be considered for
entry into the NCRN/EORTC CLOCC trial (EORTC 40044-
Chemotherapy and local ablation versus chemotherapy (5-FU
and oxaliplatin) alone).
10.0 RESECTION OF EXTRAHEPATIC COLORECTAL
METASTASES
There is evidence from cohort studies with historical controls
that survival can be improved by lung resection for
technically suitable metastatic disease.58 Long term survival
has been reported for patients who undergo resection of
pulmonary metastases when these have developed after
apparently curative resection of hepatic colorectal metas-
tases.8 Recent data suggest that if lung metastases of
colorectal origin are resectable, five year survival following
thoracotomy is similar to that observed in patients after
resection of colorectal liver metastases.59 60 It is recognised
that these encouraging survival data can be achieved in
highly selected patients but that the presence of thoracic
lymph node involvement and elevated carcinoembryonic
antigen levels before pulmonary resection are associated
with reduced survival.61 Long term survival following resec-
tion of adrenal and splenic metastases is recorded.62 63 Normal
contraindications to liver resection include uncontrollable
extrahepatic disease. Patients with advanced disease unsui-
table for liver resection or ablative therapy should be referred
to the clinical or medical oncologist with a special interest in
colorectal cancer management.
11.0 CHEMOTHERAPY AND NEOADJUVANT
CHEMOTHERAPY
There is evidence from two systematic reviews that che-
motherapy for metastatic colorectal cancer can improve
survival and should be considered in all patients not suitable
for surgery.64 65 In certain cases, tumours should be con-
sidered for downsizing with chemotherapy if they are unable
to be resected initially due to location or inadequate hepatic
functional reserve. NICE originally recommended that the
combination of oxaliplatin, 5-fluorouracil and folinic acid
should only be considered for patients with metastases
confined to the liver, and whose disease might become
resectable after chemotherapy. However, NICE now recom-
mend the use of oxaliplatin based regimens as firstline
therapy for all patients with non-resectable disease, and
irinotecan based regimens for secondline therapy after failure
of firstline treatment.66 There is no evidence to support
‘‘pretreatment’’ with neoadjuvant chemotherapy in patients
with resectable disease but the results of the recently closed
EORTC study (EPOC) are awaited. Such an approach if
employed routinely may compromise the patient’s chance of
cure. Even with the best combination chemotherapy regi-
mens, 20% of tumours will progress while on chemotherapy
and only 50% of tumours can be expected to show a partial
response to chemotherapy.2 3 66
It has been increasingly evident that tumours which were
previously thought to be irresectable can be treated by a
combination of advanced techniques with curative intent and
long term survival benefit.67 68 There is evidence that response
rates to chemotherapy in initially resectable liver only disease
may be a surrogate marker for subsequent liver resection
rates with curative intent.69 70 Concerns regarding compro-
mised hepatic functional reserve following extended hepatic
resection have led some clinicians to consider preoperative
portal vein embolisation in an attempt to increase the volume
of the intended residual liver.71 Others have suggested a two
stage hepatic resection accepting an initial non-curative
resection or ablation, but after allowing hypertrophy of the
remaining liver, the residual tumour is resected at a
subsequent operation.68 72 Therefore, decisions regarding the
feasibility of downsizing to resectability should be taken by
the regional hepatobiliary unit. As a consequence of down-
sizing, all previously identified sites should be treated by
surgery and or ablation.73 74
12.0 ABLATIVE THERAPY
The decision to offer ablative therapy to patients with hepatic
metastases should be made by the regional hepatobiliary
unit. The precise role of ablative therapy is yet to be
established, and entry into the CLOCC trial should be
considered for patients with nine or less metastases (up to
4 cm) without extrahepatic disease (EORTC 40004). Some
would consider ablative therapy for patients who do not fulfil
the criteria of the CLOCC trial. These might include patients
with associated comorbidity that precludes resection and
patients who decline surgery although there are significant
risks associated with the procedure.75 Patients with treatable
extrahepatic disease may be considered for ablative therapy.76
Patients whose tumours have been downsized by chemother-
apy but are not resectable may be considered for ablative
therapy.57 77
Patients with advanced disease unsuitable for liver resec-
tion or ablative therapy should be referred to the clinical or
medical oncologist with a special interest in colorectal cancer
for further management and supportive care.
13.0 SYNCHRONOUS METASTASES
Normally, colorectal cancer resection and liver resection
would not be performed synchronously but management of
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accessible small metastases detected preoperatively may be
considered for combined resection. Simultaneous colon and
liver resection has been shown to be safe and efficient in the
treatment of patients with colorectal cancer and synchronous
liver metastases when undertaken in high volume centres
with appropriate experience in liver resectional surgery.78
There is a significant risk of local dissemination of tumour
with biopsy of colorectal metastases79 and recent evidence has
suggested a deleterious effect on resectability and long term
survival.33 Excision of small atypical lesions should not be
considered without discussion with the regional hepatobili-
ary unit.
Patients should be referred for consideration of liver
resection after recovery from primary surgery and it seems
appropriate to allow the patient to recover from colorectal
surgery before consideration is given to a further elective
operative procedure.
14.0 FOLLOW UP AFTER LIVER RESECTION
Recurrence may occur in up to 60% of patients following liver
resection for colorectal metastases with the most common
site being in the liver. Approximately 20% of these patients
have recurrence only in the liver and therefore may be
suitable for re-resection.80 Of these, 90% are detected within
the first two years following liver resection.81 The reported
morbidity and mortality rates and long term survival rates of
re-resection are similar to those reported for the original
hepatectomy despite the greater technical difficulty of the
procedure.82 Long term survival appears to be similar to that
for the initial hepatic resection.80 82 However, patients with a
low tumour load appear to be the best candidates and the
presence of extrahepatic disease or incomplete tumour
clearance is associated with a poorer outcome.83 It therefore
seems logical to follow up such patients for five years using
CT chest and liver and blood CEA levels to identify patients
who might benefit from further intervention. It seems
appropriate to consider such lesions in the same way as the
initial hepatic metastases and to offer re-resection or ablation
to patients based on operative risk and likely survival.
15.0 THE PATIENT PERSPECTIVE: IMPACT ON
PATIENT AND FAMILY
Most of the published research on colorectal liver metastases
focuses on clinical evaluation of treatment. There is some
evidence of exploratory qualitative studies identifying the
patient perspective in relation to information needs, and also
consensus of best practice (incorporating patient perspective)
from experts in the field, but research on the organisation
and delivery of services to this population is still in its
infancy. In patients with colorectal cancer, the greatest need
for information appears to be at diagnosis, after discharge
from surgery while waiting for oncology review, and on
completion of chemotherapy.84 Healthcare professionals
should respect patients’ wishes to be involved when making
plans about their own management although a systematic
review of a large number of controlled studies was able to
conclude that interventions aimed at facilitating decision
making are under-researched and that there was more need
for randomised trials.85
Evidence and guidelines with other/heterogenous cancer
types, where the interventions and outcomes in relation to
communication, information, and the organisation of care
delivery may be expected to generalise to this population
have therefore been included.86
16.0 COMMUNICATION AND INFORMATION
The referring colorectal cancer centre should have agreed
guidelines concerning the breaking of bad news87 and
disclosure of diagnosis of colorectal liver metastases to the
patient, their carer, and to the patient’s general practitioner.
There should be written information for patients that
includes information about the provision of local specialist
cancer services for colorectal liver metastases.86
All health professionals working with patients diagnosed
with colorectal liver metastases should be competent to
communicate with sensitivity, expertise, and clarity. They
need to know how best to elicit patients’ individual
concerns,88 preferences for information, and involvement in
decisions about their treatment and care.89 They should be
competent to discuss treatment options and care choices
which enable patients to make informed decisions. These
should include the individual’s calculated risk/benefits,
acknowledged uncertainties, and side effects of any treat-
ment offered.90
Patients and their carers should be helped to access and
understand appropriate information, including that from
voluntary support services and patient self help groups, as
well as psychological, social, and spiritual/cultural sup-
port.91 92
Any locally developed written information should reflect
the opinions of representative patients with colorectal liver
metastases and their carers.91 92
17.0 MULTIDISCIPLINARY TEAM STRATEGIES AND
ORGANISATION OF CARE DELIVERY TO IMPROVE
THE QUALITY OF LIFE OF PATIENTS WITH
COLORECTAL LIVER METASTASES
Patients with cancer often have complex needs that cannot
be addressed by a single specialty or discipline. The multi-
disciplinary team should ensure a consistent and equitable
approach to planning and managing care. The clinical nurse
specialist or nurse practitioner should be part of this team
and be able to provide advice, support, and information.
Following discussion with the regional hepatobiliary unit,
the management decision is discussed ideally with the
patient in clinic, within seven days of the MDT meeting.
However, where previously agreed with the patient, this
decision can be divulged over the telephone by a member of
the MDT who has previously met the patient and is familiar
with the case. Where necessary, or if requested, a further
appointment can be made with the surgeon or medical
oncologist to discuss the treatment decision. Written con-
firmation about the treatment decision, including rationale,
should be sent to the patient’s general practitioner and if
desired a copy to the patient.87
In addition to the clinic consultation or telephone
conversation in which the treatment decision is commu-
nicated to the patient, the patient should have ongoing access
to the specialist hepatobiliary unit via the hepatobiliary
clinical nurse specialist to discuss any further information
needs or concerns. A telephone contact number, preferably
with access to a 24 hour answer phone, should be available.87
Follow up screening after treatment for colorectal liver
metastases will be discussed at the hepatobiliary unit, and
should be disclosed to patients and their carers in the format
as above.87 If long distances are involved, follow up may be
carried out by the local colorectal unit using agreed protocols.
Should recurrent disease or further metastatic spread occur,
this will be disclosed to the patient and carer in the clinic
setting.
An audit of standards should be undertaken on an annual
basis and include an audit of patient opinion and satisfaction
with organisation of care delivery.
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19.0 APPENDIX 1
PARTICIPATING BODIES
Association of Upper Gastrointestinal Surgeons
British Society of Gastroenteology
British Association of Surgical Oncology
Association of Cancer Physicians
British Oncological Association
British Association for the Study of the Liver
Royal College of Radiologists
Association of Coloproctologists




Others attending as a result of their known expertise in the
field
20.0 APPENDIX 2
THE FACS TRIAL (FOLLOW UP AFTER COLORECTAL
SURGERY)
A multicentre, randomised, controlled trial to assess the cost
effectiveness of intensive versus minimum scheduled follow
up in patients who have undergone curative resection for
colorectal cancer with curative intent.
The study aim is to assess the effect on survival of
augmenting symptomatic follow up in primary care, plus an
optional single CT scan, with two intensive methods of follow
up—monitoring of tumour marker in primary care and
intensive imaging.
The FACS trial aims to recruit 5000 patients who have
undergone resection for colorectal cancer with curative
intent. The trial objectives are overall survival, quality of life,
cost of NHS services utilised, and NHS cost per life year saved
(http://www.facs.soton.ac.uk)
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